Drugs / RX108
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03646071 | Aug 2018 → Aug 2023 | metastatic neoplasm | NeuPharma, Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RX108 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03646071 ↗ |
| Action | Inhibit | “RX108 is a novel, potent, small-molecule inhibitor of Na+/K+-ATPase.” NCT03646071 ↗ |
| Modality | Small molecule | “RX108 is a novel, potent, small-molecule inhibitor of Na+/K+-ATPase.” NCT03646071 ↗ |